Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
128.65
+0.42 (0.32%)
Sep 4, 2025, 11:09 AM - Market open
Novartis AG Revenue
Novartis AG had revenue of $14.84B in the quarter ending June 30, 2025, with 15.26% growth. This brings the company's revenue in the last twelve months to $55.19B, up 12.95% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$55.19B
Revenue Growth
+12.95%
P/S Ratio
4.50
Revenue / Employee
$727,251
Employees
75,883
Market Cap
248.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
NVS News
- 21 hours ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 1 day ago - Novartis signs up to $5.2 billion licensing deal with Argo Biopharmaceutical for heart drugs - Reuters
- 1 day ago - Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - PRNewsWire
- 1 day ago - Novartis: Pipeline Progress And Buyback Drive Upside - Seeking Alpha
- 2 days ago - Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy - Reuters
- 5 days ago - Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain - GlobeNewsWire
- 9 days ago - BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties - PRNewsWire
- 17 days ago - New Novartis ESC data highlights strength of cardiovascular portfolio - GlobeNewsWire